Safety Committee Backs PH-762 Dose-Escalation in Skin Cancer Trial
Source: Targeted Oncology, April 2025
A phase 1b trial is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma.
A safety monitoring committee (SMC) has recommended dose-escalation for a phase 1b trial (NCT06014086) evaluating PH-762 in cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma.
PH-762 is a potent RNAi molecule that targets PD-1. The agent can inhibit the immune checkpoint PD-1 in the tumor, thereby impeding tumor growth.